GLOBAL ACCESS TO RITUXIMAB FOR CHILDREN AND ADOLESCENTS DIAGNOSED WITH BURKITT LYMPHOMA: FINDINGS FROM SIOP ESSENTIAL MEDICINES WORKING GROUP SURVEY. (SIOP 2026) - Oct 23, 2026 - Abstract #VIRTUAL-086; "The survey covered respondent demographics, rituximab availability status, brand available, mechanisms of payment, barriers to access for children with cancer, and availability of subcutaneous rituximab at each institution. This survey revealed substantial differences in access to rituximab for children with BL across health systems and income settings, with notable gaps in availability and funding-related access barriers – particularly in LMICs, where BL incidence is highest. Policy efforts to address these barriers are needed to improve the extent and equity of access to rituximab for children and adolescents BL internationally."
Clinical • Burkitt Lymphoma • Hematological Malignancies • Lymphoma
|
|
Agness Chitedze1; Gilles Vassal2; Chi Kong Li2; Edith Grynszpancholc3; Gevorg Tamamyan4; Joyce Kambugu5; Liliana Vasquez2; Maria Otth2; Ramandeep Arora6; Paula Schaiquech2; Helen Irving2; Federico Antillon-Klussmann7; Susanne Wollaert8; Avram Denburg1
|